Table 2.
Demographic and baseline characteristics
| Year 1 | ||||
|
3 μg ID (N = 378) |
6 μg ID (N = 375) |
15 μg IM (N = 376) |
Total (N = 1129) |
|
| Mean age ± standard deviation | 39 ± 11 | 39 ± 12 | 39 ± 12 | 39 ± 12 |
| Male/female ratio | 0.6 | 0.7 | 1.0 | 0.7 |
| History of influenza vaccination*, n (%) | 112 (29.6) | 114 (30.4) | 100 (26.6) | 326 (28.9) |
| Reaction to previous influenza vaccination*, n (%) | 10 (8.9) | 9 (7.9) | 7 (7.0) | 26 (8.0) |
| Year 2 | ||||
|
9 μg ID (N = 544) |
15 μg IM (N = 547) |
Total (N = 1091) |
||
| mean age +/- standard deviation | 40 ± 12 | 40 ± 12 | 40 ± 11 | |
| Male/female ratio | 0.7 | 0.7 | 0.7 | |
| Year 3 | ||||
|
9 μg ID (N = 417) |
15 μg IM (N = 411) |
Total (N = 828) |
||
| mean age +/- standard deviation | 41 ± 11 | 40 ± 11 | 40 ± 11 | |
| Male/female ratio | 0.8 | 0.7 | 0.7 | |
Data are for the per protocol population for Year 1 and the safety population for Years 2 and 3. ID, intradermal; IM, intramuscular; N and n, number of subjects
*Subjects who recalled having previously received an influenza vaccination and having experienced any reactions after a previous influenza vaccination.